Cargando…
Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial
BACKGROUND: Historical reports on surgical renal denervation consistently describe renal plexus as a triangle or fan-like structure converging at the kidney gate. Following that anatomy, we developed a distal mode of radiofrequency renal denervation (RDN) mainly in segmental branches of the renal ar...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819529/ https://www.ncbi.nlm.nih.gov/pubmed/35146146 http://dx.doi.org/10.1016/j.heliyon.2022.e08747 |
_version_ | 1784646078461640704 |
---|---|
author | Pekarskiy, Stanislav Baev, Andrei Falkovskaya, Alla Lichikaki, Valeria Sitkova, Ekaterina Zubanova, Irina Manukyan, Musheg Tarasov, Mikhail Mordovin, Viktor Popov, Sergei |
author_facet | Pekarskiy, Stanislav Baev, Andrei Falkovskaya, Alla Lichikaki, Valeria Sitkova, Ekaterina Zubanova, Irina Manukyan, Musheg Tarasov, Mikhail Mordovin, Viktor Popov, Sergei |
author_sort | Pekarskiy, Stanislav |
collection | PubMed |
description | BACKGROUND: Historical reports on surgical renal denervation consistently describe renal plexus as a triangle or fan-like structure converging at the kidney gate. Following that anatomy, we developed a distal mode of radiofrequency renal denervation (RDN) mainly in segmental branches of the renal artery and confirmed its superior efficacy over the conventional main trunk procedure in a 6-months double-blind randomized controlled trial (NCT02667912). To assess the long-term effects of distal RDN we extended the follow-up of our study to three years. METHODS: BP, serum creatinine, eGFR were measured one and three years after randomization; major adverse renal events were assessed over the entire study period. The blinding was maintained over the entire three-year study period. FINDINGS: Of 55 randomized patients, 47 (23/24, distal/main trunk RDN, respectively) were assessed at one year and 39 (21/18) at three years post-procedure. Twenty-four-hour ambulatory systolic BP remained powerfully lowered after distal RDN both at one- and three-years assessments(mean change from baseline: -18.0, 95% CI -27.6 to -8.5; p<0.05 and -16·9, 95% CI -27·3 to -6·5; p<0·05, mmHg, respectively. This was accompanied by a moderate drop in eGFR at one year: -8·9 ml/min/m2, 95% CI -14·8 to -3·1; p<0·05, which, however, subsequently decreased in size at three years: -6·5, 95% CI -13·2 to 0·3; p>0·05. After main trunk RDN, the decrease of 24h systolic BP was quite moderate at one year: -12·1, 95% CI -19·2 to -5·0; p<0·05, and further weakened at three-year assessment: -8·5, 95% CI -19·7 to 2·2; p>0.05. eGFR was almost unchanged at one year: -1·3, 95% CI -6·6 to 4·0; p>0·05, but significantly decreased at three years: -5·0, 95% CI -9·6 to -0·3; p<0·05. INTERPRETATION: Our data demonstrate the durable strong BP-lowering efficacy and favorable long-term renal safety of distal RDN. |
format | Online Article Text |
id | pubmed-8819529 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88195292022-02-09 Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial Pekarskiy, Stanislav Baev, Andrei Falkovskaya, Alla Lichikaki, Valeria Sitkova, Ekaterina Zubanova, Irina Manukyan, Musheg Tarasov, Mikhail Mordovin, Viktor Popov, Sergei Heliyon Research Article BACKGROUND: Historical reports on surgical renal denervation consistently describe renal plexus as a triangle or fan-like structure converging at the kidney gate. Following that anatomy, we developed a distal mode of radiofrequency renal denervation (RDN) mainly in segmental branches of the renal artery and confirmed its superior efficacy over the conventional main trunk procedure in a 6-months double-blind randomized controlled trial (NCT02667912). To assess the long-term effects of distal RDN we extended the follow-up of our study to three years. METHODS: BP, serum creatinine, eGFR were measured one and three years after randomization; major adverse renal events were assessed over the entire study period. The blinding was maintained over the entire three-year study period. FINDINGS: Of 55 randomized patients, 47 (23/24, distal/main trunk RDN, respectively) were assessed at one year and 39 (21/18) at three years post-procedure. Twenty-four-hour ambulatory systolic BP remained powerfully lowered after distal RDN both at one- and three-years assessments(mean change from baseline: -18.0, 95% CI -27.6 to -8.5; p<0.05 and -16·9, 95% CI -27·3 to -6·5; p<0·05, mmHg, respectively. This was accompanied by a moderate drop in eGFR at one year: -8·9 ml/min/m2, 95% CI -14·8 to -3·1; p<0·05, which, however, subsequently decreased in size at three years: -6·5, 95% CI -13·2 to 0·3; p>0·05. After main trunk RDN, the decrease of 24h systolic BP was quite moderate at one year: -12·1, 95% CI -19·2 to -5·0; p<0·05, and further weakened at three-year assessment: -8·5, 95% CI -19·7 to 2·2; p>0.05. eGFR was almost unchanged at one year: -1·3, 95% CI -6·6 to 4·0; p>0·05, but significantly decreased at three years: -5·0, 95% CI -9·6 to -0·3; p<0·05. INTERPRETATION: Our data demonstrate the durable strong BP-lowering efficacy and favorable long-term renal safety of distal RDN. Elsevier 2022-01-13 /pmc/articles/PMC8819529/ /pubmed/35146146 http://dx.doi.org/10.1016/j.heliyon.2022.e08747 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Pekarskiy, Stanislav Baev, Andrei Falkovskaya, Alla Lichikaki, Valeria Sitkova, Ekaterina Zubanova, Irina Manukyan, Musheg Tarasov, Mikhail Mordovin, Viktor Popov, Sergei Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
title | Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
title_full | Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
title_fullStr | Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
title_full_unstemmed | Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
title_short | Durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
title_sort | durable strong efficacy and favorable long-term renal safety of the anatomically optimized distal renal denervation according to the 3 year follow-up extension of the double-blind randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819529/ https://www.ncbi.nlm.nih.gov/pubmed/35146146 http://dx.doi.org/10.1016/j.heliyon.2022.e08747 |
work_keys_str_mv | AT pekarskiystanislav durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT baevandrei durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT falkovskayaalla durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT lichikakivaleria durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT sitkovaekaterina durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT zubanovairina durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT manukyanmusheg durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT tarasovmikhail durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT mordovinviktor durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial AT popovsergei durablestrongefficacyandfavorablelongtermrenalsafetyoftheanatomicallyoptimizeddistalrenaldenervationaccordingtothe3yearfollowupextensionofthedoubleblindrandomizedcontrolledtrial |